Combination therapy with biologic agents in rheumatic diseases: current and future prospects

Therapeutic Advances in Musculoskeletal Disease

Volumn 8, Issue 5, 2016, Pages 192-202

  Inui, Kentaro ^a   Koike, Tatsuya ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

biologic agent; biosimilar; combination therapy; disease modifying antirheumatic drug; methotrexate; rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TRIAMCINOLONE;

ANKYLOSING SPONDYLITIS; CHRONIC LYMPHATIC LEUKEMIA; CINCA SYNDROME; COMPARATIVE EFFECTIVENESS; CROHN DISEASE; DAS28; DRUG EFFICACY; DRUG RETENTION; DRUG TREATMENT FAILURE; GRANULOMATOSIS; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MICROSCOPIC POLYANGIITIS; MONOTHERAPY; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 84988556875     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X16665330     Document Type: Review

References (59)

1. American College of Rheumatology (1996) Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 39: 713–722.
2. Atsumi T., Yamamoto K., Takeuchi T., Yamanaka H., Ishiguro N., Tanaka Y.. (2016) The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rheum Dis 75: 75–83.
3. Axelsen M., Eshed I., Horslev-Petersen K., Stengaard-Pedersen K., Hetland M., Moller J.. (2015) A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Ann Rheum Dis 74: 867–875.
4. Bakker M., Jacobs J., Welsing P., Verstappen S., Tekstra J., Ton E.. (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156: 329–339.
5. Bartelds G., Wijbrandts C., Nurmohamed M., Stapel S., Lems W., Aarden L.. (2007) Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 66: 921–926.
6. Bathon J., Robles M., Ximenes A., Nayiager S., Wollenhaupt J., Durez P.. (2011) Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Ann Rheum Dis 70: 1949–1956.
7. Blum M., Koo D., Doshi J., (2011) Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther 33: 901–913.
8. Boers M., van Tuyl L., van den Broek M., Kostense P., Allaart C., (2013) Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also ‘disconnect’ disease activity and damage in rheumatoid arthritis. Ann Rheum Dis 72: 406–409.
9. Braun J., (2011) Methotrexate: optimizing the efficacy in rheumatoid arthritis. Ther Adv Musculoskelet Dis 3: 151–158.
10. Breedveld F., Weisman M., Kavanaugh A., Cohen S., Pavelka K., van Vollenhoven R.. (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54: 26–37.
11. Burmester G., Kivitz A., Kupper H., Arulmani U., Florentinus S., Goss S.. (2015a) Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 74: 1037–1044.
12. Burmester G., Rigby W., van Vollenhoven R., Kay J., Rubbert-Roth A., Kelman A.. (2015b) Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis 75: 1081–1091.
13. Chan C., Holroyd C., Mason A., Zarroug J., Edwards C., (2016) Are there dangers in biologic dose reduction strategies? Autoimmun Rev 15: 742–746.
14. De Jong P., Hazes J., Han H., Huisman M., van Zeben D., van der Lubbe P.. (2014) Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial. Ann Rheum Dis 73: 1331–1339.
15. Dougados M., Kissel K., Conaghan P., Mola E., Schett G., Gerli R.. (2014) Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 73: 803–809.
16. Emery P., Breedveld F., Hall S., Durez P., Chang D., Robertson D.. (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372: 375–382.
17. Emery P., Deodhar A., Rigby W., Isaacs J., Combe B., Racewicz A.. (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 69: 1629–1635.
18. Emery P., Fleischmann R., Moreland L., Hsia E., Strusberg I., Durez P.. (2009) Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60: 2272–2283.
19. Emery P., Sebba A., Huizinga T., (2013) Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis 72: 1897–1904.
20. Fischer J., Hueber A., Wilson S., Galm M., Baum W., Kitson C.. (2015) Combined inhibition of tumor necrosis factor α and IL-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody. Arthritis Rheumatol 67: 51–62.
21. Gabay C., Riek M., Scherer A., Finckh A., (2015) Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology (Oxford) 54: 1664–1672.
22. Genovese M., Cohen S., Moreland L., Lium D., Robbins S., Newmark R.. (2004) Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50: 1412–1419.
23. Goekoop-Ruiterman Y., De Vries-Bouwstra J., Allaart C., van Zeben D., Kerstens P., Hazes J.. (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the best study): a randomized, controlled trial. Arthritis Rheum 52: 3381–3390.
24. Heimans L., Wevers-De Boer K., Visser K., Goekoop R., van Oosterhout M., Harbers J.. (2014) A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis 73: 1356–1361.
25. Huizinga T., Conaghan P., Martin-Mola E., Schett G., Amital H., Xavier R.. (2015) Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis 74: 35–43.
26. Kaeley G., Evangelisto A., Nishio M., Liu S., Kupper H., (2014) Impact of methotrexate dose reduction upon initiation of adalimumab on clinical and ultrasonographic parameters in patients with moderate to severe rheumatoid arthritis. Ann Rheum Dis 73: 238.
27. Kalden J., Antoni C., Alvaro-Gracia J., Combe B., Emery P., Kremer J.. (2005) Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis. J Rheumatol 32: 1620–1631.
28. Karlsson J., Neovius M., Nilsson J., Petersson I., Bratt J., van Vollenhoven R.. (2013) Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial. Ann Rheum Dis 72: 1927–1933.
29. Keystone E., Genovese M., Klareskog L., Hsia E., Hall S., Miranda P.. (2009) Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis 68: 789–796.
30. Keystone E., Heijde D., Mason D., Jr. Landewe R., Vollenhoven R., Combe B.. (2008) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58: 3319–3329.
31. Kirwan J., (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 333: 142–146.
32. Klarenbeek N., Guler-Yuksel M., van der Kooij S., Han K., Ronday H., Kerstens P.. (2011) The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the best study. Ann Rheum Dis 70: 1039–1046.
33. Klareskog L., van der Heijde D., De Jager J., Gough A., Kalden J., Malaise M.. (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675–681.
34. Kojima T., Yabe Y., Kaneko A., Takahashi N., Funahashi K., Kato D.. (2015) Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study. Rheumatology (Oxford) 54: 113–120.
35. Kremer J., Genant H., Moreland L., Russell A., Emery P., Abud-Mendoza C.. (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144: 865–876.
36. Lipsky P., van der Heijde D., St Clair E., Furst D., Breedveld F., Kalden J.. (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343: 1594–1602.
37. Maini R., Breedveld F., Kalden J., Smolen J., Davis D., Macfarlane J.. (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552–1563.
38. Matsuno H., Okada M., Sakai Y., Abe C., Katayama K., Sagawa A.. (2016) The usefulness of a new triple combination treatment utilizing methotrexate, salazosulfapyridine, and bucillamine in rheumatoid arthritis. Mod Rheumatol 26: 51–56.
39. Miyasaka N., Yamanaka H., Ito H., Endo H., Kaneko Y., Kamatani N.. (2014) Guidelines for the Treatment of Rheumatoid Arthritis, Japan College of Rheumatology, Vol. 1, 1st ed. Tokyo: Medical Review.
40. Moreland L., O’Dell J., Paulus H., Curtis J., Bathon J., St Clair E.. (2012) A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 64: 2824–2835.
41. Nielen M., van Schaardenburg D., Reesink H., van de, Stadt R., van der Horst-Bruinsma I., De Koning M.. (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 50: 380–386.
42. Nishina N., Kaneko Y., Kameda H., Kuwana M., Takeuchi T., (2013) Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression. Clin Rheumatol 32: 1661–1666.
43. O’Dell J., Mikuls T., Taylor T., Ahluwalia V., Brophy M., Warren S.. (2013) Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 369: 307–318.
44. Rigby W., Mease P., Olech E., Ashby M., Tole S., (2013) Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study. J Rheumatol 40: 599–604.
45. Singer O., Gibofsky A., (2011) Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011? Curr Opin Rheumatol 23: 288–292.
46. Singh J., Saag K., Bridges S., Jr. Akl E., Bannuru R., Sullivan M.. (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 68: 1–25.
47. Smolen J., Breedveld F., Burmester G., Bykerk V., Dougados M., Emery P.. (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75: 3–15.
48. Smolen J., Landewe R., Breedveld F., Buch M., Burmester G., Dougados M.. (2014a) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73: 492–509.
49. Smolen J., van der Heijde D., Machold K., Aletaha D., Landewe R., (2014b) Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis 73: 3–5.
50. Smyth C., (1972) Therapy of rheumatoid arthritis. A pyramidal plan. Postgrad Med 51: 31–39.
51. St Clair E., van der Heijde D., Smolen J., Maini R., Bathon J., Emery P.. (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50: 3432–3443.
52. Svensson B., Boonen A., Albertsson K., van der Heijde D., Keller C., Hafstrom I., (2005) Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 52: 3360–3370.
53. Tak P., Rigby W., Rubbert-Roth A., Peterfy C., van Vollenhoven R., Stohl W.. (2011) Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70: 39–46.
54. Takeuchi T., Harigai M., Tanaka Y., Yamanaka H., Ishiguro N., Yamamoto K.. (2013) Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks. Ann Rheum Dis 72: 1488–1495.
55. Verschueren P., De Cock D., Corluy L., Joos R., Langenaken C., Taelman V.. (2015) Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the careRA trial. Ann Rheum Dis 74: 27–34.
56. Weinblatt M., Keystone E., Furst D., Moreland L., Weisman M., Birbara C.. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48: 35–45.
57. Westhovens R., Robles M., Ximenes A., Nayiager S., Wollenhaupt J., Durez P.. (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68: 1870–1877.
58. Wilske K., Healey L., (1989) Remodeling the pyramid: a concept whose time has come. J Rheumatol 16: 565–567.
59. Zhang J., Xie F., Delzell E., Yun H., Lewis J., Haynes K.. (2015) Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 67: 624–632.